


# Trailblazing AI Driven Early Cancer Diagnostics & Therapeutics for Detection with Nvidia Super Computing: NASDAQ: RENB

*Revolutionizing Cancer Detection: AI-Powered Diagnostics with Nvidia Super Computing: Nasdaq: RENB*

LOS ANGELES, CALIFORNIA, UNITED STATES, April 25, 2024

/EINPresswire.com/ -- Trailblazing AI-Driven Early Cancer Diagnostics and Therapeutics for Detection with Nvidia Super Computing Power; Acquiring 100% Ownership of Cyclomics; Renovaro Inc. ([Nasdaq: RENB](https://www.nasdaq.com/markets/renb))



\$RENB is Working with \$NVDA and Oxford Nanopore for Sequencing Technology and Front Edge Software Solutions

“

We are excited to join forces with Renovaro to drive the next wave of innovation in molecular biology integrated into an advanced proprietary AI/ML platform”

*Alessio Marcozzi, CSO of  
Cyclomics*

For more information on this Exciting NASDAQ Company: RENB visit: <http://www.renovarobio.com>


Renovaro [Inc \(Nasdaq: RENB\)](https://www.nasdaq.com/markets/renb) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Bio with its advanced cell-gene immunotherapy company and RenovaroCube. RenovaroCube has developed an award-

winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

Upon the closing of the acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This has the potential to transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.

RENB announces a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore is a leader in sequencing technologies and Nvidia will provide vital supercomputing power and front-edge software solutions such as Parabricks, BioNeMo, Monai, and Nemo.


Initially set at a 75% acquisition, this decision to acquire the remaining 25% of Cyclomics reflects the resounding success of their partnership and the remarkable synergy between the two companies. Upon



NASDAQ: \$RENB



\$RENB AI Healthcare



\$RENB Strategic Partners

Upon

closing, we believe the acquisition of Cyclomics into the Renovaro family will further strengthen our ability to create a powerhouse for cancer diagnostics throughout the entire patient journey, from early detection/recurrence and personalized treatment in late-stage disease

RENBs Combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.

DISCLAIMER: <https://corporateads.com/disclaimer/>  
All Disclosures listed on the [www.corporateads.com](http://www.corporateads.com)

The Hon. Mark Dybul, MD, CEO  
Renovaro Biosciences Inc  
+1 732-780-5036

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/706484542>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.